Artwork

Content provided by Education Neurocritical Care and Neurocritical Care Society. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Education Neurocritical Care and Neurocritical Care Society or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

HOT TOPICS - ANNEXA-I Trial

1:01:20
 
Share
 

Manage episode 424352436 series 1459666
Content provided by Education Neurocritical Care and Neurocritical Care Society. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Education Neurocritical Care and Neurocritical Care Society or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion had not been well studied, until the ANNEXA-I Trial. To discuss this week's Hot Topic, Nicholas Morris, MD is joined by one of the trial's collaborators, Ashkan Shoamanesh, MD as well as clincial pharmacist Andrew Webb, PharmD, BCCCP.

Listeners can also join the NCS Journal Club which will be discussing the ANNEXA-I Trial on "X" / Twitter on Tuesday, July 16th starting at 9am CT.

  continue reading

102 episodes

Artwork
iconShare
 
Manage episode 424352436 series 1459666
Content provided by Education Neurocritical Care and Neurocritical Care Society. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Education Neurocritical Care and Neurocritical Care Society or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion had not been well studied, until the ANNEXA-I Trial. To discuss this week's Hot Topic, Nicholas Morris, MD is joined by one of the trial's collaborators, Ashkan Shoamanesh, MD as well as clincial pharmacist Andrew Webb, PharmD, BCCCP.

Listeners can also join the NCS Journal Club which will be discussing the ANNEXA-I Trial on "X" / Twitter on Tuesday, July 16th starting at 9am CT.

  continue reading

102 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide